[{"orgOrder":0,"company":"SciTech Development","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciTech Development, LLC Submits COVID-19 Treatment with Proven Antiviral Activity to U.S. Health & Human Services (HHS)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by SciTech Development
SciTech's primary drug candidate, ST-001 (fenretinide), is currently undergoing Phase I clinical trials in IV infusion form for treating patients with T-cell non-Hodgkin's lymphoma, including Peripheral T-cell Lymphoma and Sezary Syndrome.
Fenretinide has demonstrated preclinical in-vitro antiviral activity against a number of viruses including MERs, Dengue, Zika, West Nile, HIV, and HCV.